Opioid prescription by gynecologic oncologists: An analysis of Medicare Part D claims

被引:1
|
作者
Samuel, David [1 ,2 ]
Nevadunsky, Nicole S. [2 ,3 ,4 ]
Miller, Devin T. [2 ,3 ]
Isani, Sara [2 ,3 ,4 ]
Kuo, Dennis Y. S. [2 ,3 ,4 ]
Gressel, Gregory M. [2 ,3 ,4 ]
机构
[1] Montefiore Med Ctr, Dept Obstet & Gynecol & Womens Hlth, 1300 Morris Pk Ave,Block Bldg Rm 628, Bronx, NY 10461 USA
[2] Albert Einstein Coll Med, 1300 Morris Pk Ave,Block Bldg Rm 628, Bronx, NY 10461 USA
[3] Montefiore Med Ctr, Div Gynecol Oncol, Dept Obstet & Gynecol & Womens Hlth, Bronx, NY USA
[4] Albert Einstein Coll Med, Albert Einstein Canc Ctr, Bronx, NY USA
关键词
Center for Medicaid and Medicare Services; Gynecologic oncology; Medicare Part D; Opioid; Opioid claim; Opioid epidemic; Opioid prescription; Prescriber demographics; Palliative care;
D O I
10.1016/j.currproblcancer.2020.100655
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The use of opioids across all specialties has increased greatly over the last 2 decades and along with it, opioid misuse, overdose and death. The contribution of opioids prescribed for gynecologic cancers to this problem is unknown. Data from other surgical specialties show prescriber factors including gender, geographic location, board certification, experience, and fellowship training influence opioid prescribing. To characterize national-level opioid prescription patterns among gynecologic oncologists treating Medicare beneficiaries. The Centers for Medicare and Medicaid Services database was used to access Medicare Part D opioid claims prescribed by gynecologic oncologists in 2016. Prescription and prescriber characteristics were recorded including medication type, prescription length, number of claims, and total day supply. Region of practice was determined according to the US Census Bureau Regions. Board certification data were obtained from American Board of Obstetrics and Gynecology website. Bivariate statistical analysis and linear regression modeling were performed using Stata version 14.2. In 2016, 494 board-certified US gynecologic oncologists wrote 24,716 opioid prescriptions for a total 267,824 days of treatment (median 8 [interquartile range {IQR} 6, 11] prescribed days per claim). Gynecologic oncologists had a median of 33 opioid claims (IQR 18, 64). Male physicians had significantly more opioid prescription claims than females ( P < 0.01) including after adjustment for differences in years of experience. There was no difference in prescribed days per claim between male and female physicians. Physicians in the South had the greatest number of opioid prescription claims and significantly more than physicians in all other regions ( P 0.01). Gynecologic oncologists who were board certified for 15 years had a greater number of median opioid claims (28 IQR 16, 50) than those with < 5 years since board certification (22 IQR 15, 38) ( P = 0.04). Physicians who were board certified in palliative care (n = 19) had significantly more opioids claims (median 40; IQR 18, 91) than those without (median 32; IQR 18, 64) ( P < 0.01). In 2016, there were gender-based, regional, and experience-related variations in opioid prescribing by providers caring for Medicare-insured patients. (c) 2020 Elsevier Inc. All rights reserved.
引用
收藏
页数:8
相关论文
共 50 条
  • [11] Characterizing Opioid Prescribing Trends of Medical Oncologists From 2013 to 2019: Analysis From the Centers for Medicare & Medicaid Services Medicare Part D Prescribers Database
    Korst, Mark R.
    Teles, Marco Santos
    Choudhry, Hassaam S.
    Santitoro, Joseph G.
    Garcia, Daniel J.
    Schwab, Sophia Marie T.
    Kra, Joshua A.
    JCO ONCOLOGY PRACTICE, 2024, 20 (02) : 268 - 277
  • [12] Changes in Opioid Prescribing Patterns Among Generalists and Oncologists for Medicare Part D Beneficiaries From 2013 to 2017
    Agarwal, Ankit
    Roberts, Andrew
    Dusetzina, Stacie B.
    Royce, Trevor J.
    JAMA ONCOLOGY, 2020, 6 (08) : 1271 - 1274
  • [13] Opioid prescribing patterns among generalists & oncologists for Medicare Part D beneficiaries from 2013-2017.
    Royce, Trevor Joseph
    Roberts, Andrew
    Dusetzina, Stacie
    Agarwal, Ankit
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [14] COST MINIMIZATION ANALYSIS OF EQUIPOTENT OPIOID ANALGESICS: NATIONWIDE ANALYSIS OF MEDICARE PART D STAND-ALONE PRESCRIPTION DRUG PLANS
    Li, H.
    Patel, R.
    VALUE IN HEALTH, 2015, 18 (03) : A298 - A298
  • [15] DUAL USE OF VA AND MEDICARE PART D PRESCRIPTION BENEFITS AND RISK OF CONCURRENT OPIOID/BENZODIAZEPINE USE
    Carico, Ronald
    Zhao, Xinhua
    Thorpe, Carolyn T.
    Thorpe, JoshuaM.
    Sileanu, Florentina
    Cashy, John P.
    Hale, Jennifer A.
    Mor, Maria K.
    Radomski, Thomas R.
    Hausmann, Leslie R.
    Donohue, Julie M.
    Suda, K. J.
    Hanlon, Joseph
    Good, Chester
    Fine, Michael J.
    Gellad, Walid F.
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2018, 33 : S172 - S172
  • [16] A Comparison of Pharmacologic Pain and Psychiatric Management by Radiation Oncologists and Medical Oncologists in Medicare Part D
    Maroongroge, S.
    Roberts, K. B.
    Yu, J. B.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02): : E511 - E512
  • [17] Medicare Part D Prescription Drug Benefit - Part 1 of 2
    Klein, Cathy A.
    NURSE PRACTITIONER, 2006, 31 (02): : 61 - 61
  • [18] Opioid use in older adults and Medicare Part D
    Sabety, Adrienne H.
    Sherry, Tisamarie B.
    Maestas, Nicole
    HEALTH SERVICES RESEARCH, 2021, 56 (02) : 289 - 298
  • [19] Recent Medicare Part D beneficiary claims for desmopressin medications
    Johnson, Theodore M., II
    Suvada, Kara
    Plantinga, Laura C.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2021, 69 (07) : 2030 - 2032
  • [20] Annual trends in Medicare part D prescription claims for calcipotriene/betamethasone dipropionate foam for psoriasis 2016-2020
    Smith, Brandon
    Oulee, Aislyn
    Devjani, Shivali
    Collier, Michael R.
    Egeberg, Alexander
    Wu, Jashin J. J.
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2023, 62 (08) : E443 - E445